Retatrutide Clinical Trials Explained: Phase 2, Phase 3 and the TRIUMPH Program
A research-use-only guide to LY3437943 clinical trial development, including Phase 1 background, Phase 2 publications, Phase 3 TRIUMPH studies, registered endpoints, and what researchers are watching next.
Retatrutide clinical trials have evaluated LY3437943 as an investigational GLP-1, GIP, and glucagon receptor triple agonist. Published Phase 2 studies have reported controlled clinical research in obesity and type 2 diabetes settings, while ClinicalTrials.gov lists multiple Phase 3 Retatrutide studies, including TRIUMPH-related research in obesity, osteoarthritis of the knee, cardiovascular outcomes, kidney outcomes, type 2 diabetes, and other metabolic contexts. Retatrutide is not approved by the FDA or Health Canada as a medication. Luxara Labs provides Retatrutide strictly for laboratory research use only, not for human or animal use.
What this page explains
Retatrutide clinical trial searches are usually trying to answer three questions: what has been published, what is still in Phase 3, and what remains unknown. This page separates those questions clearly.
For the Retatrutide resource library, start with the Retatrutide Research Hub. For product documentation, review the Retatrutide research product page. For a Canada-focused overview, see Retatrutide Canada.
Key takeaways
- Retatrutide is the public name for LY3437943 in clinical research literature.
- Published Phase 2 studies have evaluated obesity and type 2 diabetes research populations.
- ClinicalTrials.gov lists Phase 3 Retatrutide studies across several metabolic and cardiometabolic research contexts.
- TRIUMPH-related searches should be handled as clinical research context, not as approval or availability claims.
- Retatrutide remains investigational and is not FDA approved or Health Canada approved.
- Luxara Labs supplies Retatrutide for laboratory research use only, with documentation-focused sourcing resources.
Review Retatrutide through a documentation-first lens
Luxara Labs Research Company focuses on transparent, research-use-only peptide education, third-party testing, and high-purity compounds for qualified laboratory research. Clinical trial interest should not be confused with approved medical use.
Clinical trial timeline
Retatrutide has moved from early safety and pharmacokinetic research into Phase 2 publications and broader Phase 3 development. The public record includes peer-reviewed papers and registry entries.
| Stage | Public research record | What it tells researchers | What it does not prove |
|---|---|---|---|
| Early LY3437943 research | ClinicalTrials.gov lists Phase 1 studies in healthy participants and defined pharmacokinetic settings. | Early tolerability, exposure, and study-design background. | It does not establish approved use or broad clinical conclusions. |
| Phase 2 obesity research | The NEJM Phase 2 publication evaluated a triple hormone receptor agonist in an obesity research population. | Controlled clinical evidence for endpoints reported by the investigators. | It does not replace Phase 3 evidence or regulatory review. |
| Phase 2 type 2 diabetes research | The Lancet Phase 2 publication evaluated Retatrutide in a type 2 diabetes research population. | Clinical data for glycemic and metabolic endpoints under study conditions. | It does not mean Retatrutide is approved for type 2 diabetes. |
| Phase 3 TRIUMPH program | Registry records list Phase 3 studies in obesity, type 2 diabetes, kidney outcomes, cardiovascular outcomes, and related areas. | Later-stage clinical development questions and endpoint structure. | It does not guarantee approval, release timing, or future labeling. |
Phase 1 overview
Phase 1 Retatrutide studies provide early clinical research context for LY3437943 before larger efficacy-oriented trials.
What Phase 1 generally evaluates
Phase 1 studies usually examine safety observations, tolerability, pharmacokinetic behavior, and how a compound is handled under tightly controlled clinical research conditions.
Retatrutide Phase 1 examples
ClinicalTrials.gov lists LY3437943 studies in healthy participants, participants with impaired renal function, participants with hepatic impairment, and device or pharmacokinetic research settings.
These studies are important because they help define research questions for later trials. They are not medical instructions, purchasing guidance, or evidence of approved use.
Phase 2 overview
The most cited public Retatrutide evidence comes from peer-reviewed Phase 2 studies in obesity and type 2 diabetes research settings.
| Phase 2 publication | Research population | Core scientific relevance | Source |
|---|---|---|---|
| Triple-Hormone-Receptor Agonist Retatrutide for Obesity | Participants in an obesity research setting | Evaluated Retatrutide as a triple hormone receptor agonist in a controlled Phase 2 study. | PubMed PMID 37366315 |
| Retatrutide for people with type 2 diabetes | Participants with type 2 diabetes in a controlled Phase 2 study | Evaluated Retatrutide as a GIP, GLP-1, and glucagon receptor agonist. | PubMed PMID 37385280 |
Phase 3 TRIUMPH program overview
Retatrutide Phase 3 research is commonly discussed through the TRIUMPH program. Public registry records show a broad clinical development effort across metabolic and cardiometabolic research areas.
| Phase 3 research area | Example registry record | Status context observed in public records | Why researchers track it |
|---|---|---|---|
| Obesity and overweight research | NCT05929066 | Completed record listed in ClinicalTrials.gov data retrieved June 2026. | Central Phase 3 evidence stream for Retatrutide search interest. |
| Knee osteoarthritis with obesity or overweight | NCT05931367 | Completed record listed in ClinicalTrials.gov data retrieved June 2026. | Connects body-weight endpoints with joint-related clinical outcomes under trial conditions. |
| Type 2 diabetes and obesity or overweight | NCT05929079 | Active, not recruiting record listed in ClinicalTrials.gov data retrieved June 2026. | Connects Retatrutide with glycemic and metabolic research questions. |
| Cardiovascular and kidney outcomes | NCT06383390 | Active, not recruiting record listed in ClinicalTrials.gov data retrieved June 2026. | Tracks major outcomes rather than only intermediate metabolic markers. |
| Type 2 diabetes with renal impairment | NCT06297603 | Active, not recruiting record listed in ClinicalTrials.gov data retrieved June 2026. | Addresses a more specific metabolic and renal research population. |
For broader mechanism context, see GLP-1, GIP and triple agonist peptides. For existing Phase 3 coverage on Luxara, see TRIUMPH-1 Retatrutide results and TRIUMPH-4 Retatrutide results.
TRIUMPH-1 explained
TRIUMPH-1 is a major Retatrutide Phase 3 search topic because it is associated with obesity and overweight clinical research questions.
Luxara Labs treats TRIUMPH-1 as a clinical research topic. A Phase 3 record or result does not mean Retatrutide is approved, released, or appropriate for medical use. Researchers should separate endpoint reporting from regulatory decisions.
The most useful way to read TRIUMPH-1 coverage is to ask what population was studied, what endpoints were evaluated, what was reported, what remains unpublished or under review, and whether findings have passed through peer review or regulatory assessment. Luxara’s dedicated TRIUMPH-1 page covers the search intent directly.
TRIUMPH-4 explained
TRIUMPH-4-related searches focus on Retatrutide Phase 3 research involving obesity or overweight and knee osteoarthritis context.
TRIUMPH-4 should be discussed as clinical trial evidence and endpoint reporting. It should not be described as personal health guidance, treatment advice, or proof of approved medical availability.
Luxara’s TRIUMPH-4 Retatrutide page gives a focused overview. Researchers comparing the compound to adjacent incretin research models can also review Retatrutide vs Tirzepatide, Retatrutide vs Semaglutide, and Retatrutide vs CagriSema.
Other ongoing or relevant Retatrutide trials
ClinicalTrials.gov lists additional Retatrutide studies beyond the most searched Phase 2 and TRIUMPH topics. These records show how broad the research program has become.
Kidney and cardiovascular outcomes
Registered studies evaluate Retatrutide in populations with obesity or overweight and cardiovascular or kidney outcome questions.
Type 2 diabetes research
Several records evaluate glycemic endpoints, comparison questions, renal impairment context, or metabolic outcomes in type 2 diabetes research settings.
Hepatic and metabolic research
Records include hepatic impairment and MASLD-related research contexts. These are relevant to later Luxara cluster pages on liver fat, MASLD, and MASH.
For regulatory context, use Research Use Regulations Canada and Peptide Research Regulations USA. For trust and documentation review, use Transparency, Quality Standard, and Peptide Purity Standards Canada.
What researchers are watching next
The next phase of Retatrutide interest is less about whether the compound has trial activity and more about how the evidence matures.
| Question researchers are watching | Why it matters | Safe interpretation |
|---|---|---|
| Which Phase 3 results are peer reviewed? | Peer review helps distinguish preliminary reporting from journal-level evidence. | Use published sources where available and label registry or press information clearly. |
| How do endpoints differ across populations? | Obesity, type 2 diabetes, kidney, cardiovascular, osteoarthritis, and liver research settings are not interchangeable. | Avoid merging findings from different populations into a single claim. |
| What safety patterns appear across studies? | Adverse-event reporting is central to later clinical development. | Report study observations only and do not provide management advice. |
| How does Retatrutide compare with dual agonist or GLP-1-focused models? | Mechanism comparisons affect research interpretation. | Compare receptor systems and published evidence, not personal outcomes. |
What remains unknown
A strong Retatrutide page should be clear about uncertainty. Serious research content does not pretend that every question has already been resolved.
Regulatory outcomes
Approval decisions depend on submitted data, agency review, labeling assessment, and benefit-risk evaluation. Registry status alone does not predict approval.
Longer-term evidence
Phase 3 trials help expand the evidence base, but longer-term comparative data and publication depth still matter for scientific interpretation.
Population-specific findings
Findings from one clinical research population cannot automatically be applied to another population or endpoint category.
Laboratory material evaluation
Clinical trial evidence does not replace COA review, lab-result resources, lot documentation, and supplier transparency for research materials.
Research-use context
Clinical trials and laboratory research material sourcing are separate contexts. Luxara Labs keeps that distinction visible because it protects researchers, the brand, and the integrity of the content.
Retatrutide offered by Luxara Labs is for laboratory research use only. It is not for human consumption, animal use, diagnosis, treatment, prevention, or therapeutic application. Luxara Labs does not provide medical advice, dosing guidance, administration instructions, or research protocols.
Researchers evaluating Retatrutide should consider purity, documentation, storage, handling, and supplier transparency. Luxara Labs publishes available lab results and provides educational resources to help researchers evaluate peptide quality and documentation. Review Lab Results, How to Read a COA, and Peptide Storage, Handling and Stability.
Related Retatrutide research pages
These pages build the Retatrutide topic cluster around mechanism, Phase 3 interpretation, comparisons, regulatory context, and research availability.
Related Luxara Labs authority pages
Research Summary
Retatrutide clinical trials evaluate LY3437943, an investigational GLP-1, GIP, and glucagon receptor triple agonist. Published Phase 2 studies have reported Retatrutide clinical research in obesity and type 2 diabetes settings. ClinicalTrials.gov lists Phase 3 Retatrutide studies across obesity, overweight, type 2 diabetes, knee osteoarthritis, cardiovascular outcomes, kidney outcomes, renal impairment, MASLD, and related metabolic research areas. TRIUMPH-1 and TRIUMPH-4 are major Retatrutide Phase 3 search topics, but Retatrutide is not approved as a medication by the FDA or Health Canada. Luxara Labs provides Retatrutide only for laboratory research use and not for human or animal use.
| Entity | Extraction-ready definition |
|---|---|
| Retatrutide | Investigational triple agonist peptide also known as LY3437943. |
| LY3437943 | Development code used for Retatrutide in publications and trial records. |
| Phase 2 | Controlled clinical research stage with published obesity and type 2 diabetes Retatrutide studies. |
| Phase 3 | Later-stage clinical trial research covering larger or more specific populations and endpoints. |
| TRIUMPH | Retatrutide Phase 3 program context tracked by researchers and searchers. |
| Clinical research | Human clinical trial evidence generated under formal study conditions. |
| Laboratory research material | Research-use-only material evaluated through documentation, COA resources, and supplier transparency. |
Review Retatrutide research availability and documentation
Use the clinical trial literature for scientific context, then use Luxara’s product page, lab-result resources, and COA education to evaluate research material documentation.
Retatrutide clinical trials FAQ
Retatrutide clinical trials are studying LY3437943 as an investigational GLP-1, GIP, and glucagon receptor triple agonist in metabolic and cardiometabolic research contexts.
Yes. Peer-reviewed Phase 2 publications have reported Retatrutide research in obesity and type 2 diabetes clinical trial settings.
Yes. ClinicalTrials.gov lists multiple Phase 3 Retatrutide studies across obesity, type 2 diabetes, cardiovascular outcomes, kidney outcomes, and related areas.
TRIUMPH is the Phase 3 Retatrutide clinical development context commonly associated with obesity, metabolic, cardiometabolic, and outcome-focused research questions.
No. Retatrutide is not FDA approved as a medication. It remains an investigational compound in clinical development.
No. The clinical-trials page summarizes study status and design context only, while approval status is handled on the dedicated regulatory page. Luxara Labs discusses Retatrutide only in research-use-only contexts.
No. Clinical trial findings are scientific evidence generated under formal study conditions. They are not personal-use instructions or medical advice.
Researchers should review COA resources, lab-result availability, purity documentation, lot details, storage context, handling information, and supplier transparency.
Research references
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023. PubMed
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023. PubMed
- ClinicalTrials.gov. Retatrutide and LY3437943 study registry records. ClinicalTrials.gov search
- ClinicalTrials.gov. NCT04881760, Phase 2 obesity or overweight Retatrutide study record. NCT04881760
- ClinicalTrials.gov. NCT04867785, Phase 2 type 2 diabetes Retatrutide study record. NCT04867785
- ClinicalTrials.gov. NCT05929066, Phase 3 Retatrutide obesity or overweight study record. NCT05929066
- ClinicalTrials.gov. NCT05931367, Phase 3 Retatrutide knee osteoarthritis study record. NCT05931367
- ClinicalTrials.gov. NCT06383390, TRIUMPH-Outcomes Retatrutide cardiovascular and kidney outcomes record. NCT06383390
- U.S. Food and Drug Administration. Drugs@FDA approved drug database. FDA Drugs@FDA
- Health Canada. Drug Product Database. Health Canada DPD
Retatrutide and all compounds discussed on this page are provided for laboratory research use only. They are not intended for human consumption, animal use, diagnosis, treatment, prevention, or therapeutic application. Luxara Labs does not provide medical advice, dosing guidance, administration instructions, or research protocols.